CG MedTech Co

CG MedTech Co Debt/EBITDA

The Total Debt to EBITDA Ratio of CG MedTech Co (056090.KQ) as of Oct 15, 2026 is 0.23. In the previous year, Total Debt to EBITDA Ratio was -4.40 — a change of -105.12% (higher).

Debt/EBITDA

0.23

YoY

-105.12%

Last updated:

Total Debt to EBITDA Ratio of CG MedTech Co is 2025 0.23 . Total Debt to EBITDA Ratio of CG MedTech Co was 2024 -4.40 . It decreases by -105.12% higher compared to the previous year.

The CG MedTech Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
-3.34 KRW
Jan 1, 2018
-1.99 KRW
Jan 1, 2019
-44.20 KRW
Jan 1, 2020
-2.34 KRW
Jan 1, 2021
-7.10 KRW
Jan 1, 2022
52.68 KRW
Jan 1, 2024
-4.40 KRW
Jan 1, 2025
0.23 KRW
The CG MedTech Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.23-105.12%
-4.40-108.36%
52.68-841.88%
-7.10+203.48%
-2.34-94.71%
-44.20+2,125.00%
-1.99-40.46%
-3.34+200.37%
-1.11-83.96%
-6.92-175.68%
9.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG MedTech Co Stock analysis

What does CG MedTech Co do? CG MedTech Co Ltd, listed on the Korea Exchange with ticker 056090.KQ and ISIN KR7056090004, is a company based in Uijeongbu, South Korea. It operates within the Health Care sector, specifically in the Health Care industry. The company went public on November 12, 2015. Its website is https://inno-sys.net/. CG MedTech Co Ltd focuses on the manufacture of orthopaedic surgical implants and surgical devices. The company's business activities are conducted through two segments: the Medical Device Business segment, which involves the production and sale of spinal fixation devices, micro-invasive medical devices for back pain treatment, fracture treatment devices, and bioabsorbable alloy implants, and the Electric Energy Business segment, which is involved in the production and sale of electricity meters and integrated calorimeters. The company's headquarters are located in Uijeongbu, Gyeonggi-Do. The website provided is associated with the company, though the source description mentions 'Innosys Co. Ltd.' as the company name, which may differ from the official name. The source also indicates that the company's IPO date is November 12, 2015, which aligns with the provided information. The company's operations are centered around medical devices, with a secondary focus on electric energy products. CG MedTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG MedTech Co stock

Total Debt to EBITDA Ratio of CG MedTech Co is 0.23 in 2025.

Total Debt to EBITDA Ratio of CG MedTech Co changed from -4.40 to 0.23, representing a -105.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio CG MedTech Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's CG MedTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CG MedTech Co

All Key Metrics — CG MedTech Co